Lincoln Pharmaceuticals Ltd reported a 16.93% year-on-year increase in standalone net profit to ₹27.70 crore for the first quarter of FY26, compared to ₹23.69 crore in Q1 FY25. Total income for Q1 FY26 was ₹169.34 crore, up 7.39% from ₹157.69 crore in Q1 FY25.
Metric | Q1 FY26 | Q1 FY25 | YoY Change |
---|---|---|---|
Total Income | 169.34 | 157.69 | 7.39% |
EBITDA | 39.08 | 33.14 | 17.92% |
PBT | 35.39 | 29.48 | 20.05% |
Net Profit | 27.70 | 23.69 | 16.93% |
E.P.S (₹) | 13.82 | 11.82 | 16.92% |
EBITDA for Q1 FY26 was ₹39.08 crore, a 17.92% increase compared to ₹33.14 crore in Q1 FY25. The company's EPS for Q1 FY26 stood at ₹13.82.
The company aims to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Lincoln Pharma is targeting revenue of ₹1,000 crore in the next three years. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company, rising from 3.95% in June 2024 to 5.13% as of June 2025.
During the quarter, Lincoln Pharma started its Bulk Drug Manufacturing Plant, for which product approval has been received for 10 products, with others under process. The company plans to invest ₹4 crore in this plant from internal accruals.
The company's growth strategy focuses on expanding its global footprint by registering new products for export, enhancing domestic market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company's liquidity remains solid.
Lincoln Pharma is focused on strengthening its presence in regulated and semi-regulated markets and currently exports to over 60 countries across East and West Africa, Central and North America, Latin America, and Southeast Asia. The company aims to expand this footprint to 90 countries over the next 2-3 years. With recent entry into the Canadian market and approvals from TGA - Australia and EU GMP, the company is poised for further global expansion.
The company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company showcases its dedication to innovation and growth through a robust portfolio boasting over 1,700 registered products, with 700 more in development.
Consolidated Results includes results of its subsidiary namely Zullinc Healthcare LLP.
The Board of Directors also re-appointed Mr. Mahendra G. Patel as the Managing Director, and Mr. Hashmukh I. Patel, Mr. Ashish R. Patel, and Mr. Munjal M. Patel as Whole Time Directors for a term of 5 years, subject to shareholders' approval.
M/s Ankit Sethi & Associates were appointed as Secretarial Auditor of the Company for the Financial Year starting from April 01, 2025, for a term of 5 years, subject to Shareholders' Approval in ensuing Annual General Meeting of the Company.
Darshit A. Shah (CFO) can be contacted at +91-79-4107-8048 or darshit@lincolnpharma.com for further information.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.